Huperzine A

Chembox new
Name = Huperzine A
ImageFile = Huperzine A.png ImageSize = 200px
ImageName = Huperzine A
ImageFile1 = HuperzineA3d.png ImageSize1 = 200px
ImageName1 = Huperzine A 3d
IUPACName = (1"R",9"S",13"E")-1-Amino-13-ethylidene- 11-methyl-6-azatricyclo [7.3.1.0^2,7] trideca- 2(7),3,10-trien-5-one
OtherNames = HupA
Section1 = Chembox Identifiers
SMILES = CC3=CC1/C(C(C3)(N)C(C=CC2=O)=C(N2)C1)=CC
CASNo = 102518-79-6
RTECS =
Section2 = Chembox Properties
Formula = C₁₅H₁₈N₂O
MolarMass = 242.32 g/mol
Appearance =
Density =
Solubility =
MeltingPt = 217-219 °C
BoilingPt =
pKb =
Section7 = Chembox Hazards
ExternalMSDS =
MainHazards =
FlashPt =
RPhrases =
SPhrases =
Section8 = Chembox Related
OtherCpds =

Huperzine A, is a naturally occurring sesquiterpene alkaloid found in the plant extracts of the firmoss "Huperzia serrata". [cite journal | author = Kozikowski, Alan P.; Tueckmantel, Werner | title = Chemistry, Pharmacology, and Clinical Efficacy of the Chinese Nootropic Agent Huperzine A | journal = Accounts of Chemical Research | year = 1999 | volume = 32 | issue = 8 | pages = 641–650 | doi = 10.1021/ar9800892]

The botanical has been used in China for centuries for the treatment of swelling, fever and blood disorders. In the West, it is used as an herbal supplement and is not approved for pharmaceutical use. Recently in clinical trials in China, it has demonstrated neuroprotective effects.

Huperzine A has also attracted the attention of Western medical science. It is currently being investigated as a possible treatment for diseases characterized by neurodegeneration – particularly Alzheimer’s disease. [cite journal | author = Zangara, A | title = The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer's disease | journal = Pharmacol Biochem Behav. | year = 2003 | volume = 75 | issue = 3 | pages = 675–86 | doi = 10.1016/S0091-3057(03)00111-4] [cite journal | author = Bai, D. L.; Tang, X. C.; He, X. C. | title = Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease | journal = Current Medicinal Chemistry | year = 2000 | volume = 7 |issue= 3 | pages = 355–374] It has been found to be an inhibitor of the enzyme acetylcholinesterase. [cite journal | author = Tang, X. C.; He, X. C.; Bai, D. L. | title = Huperzine A: a novel acetylcholinesterase inhibitor | journal = Drugs of the Future | year = 1999 | volume = 24 | issue = 6 | pages = 647–663 | doi = 10.1358/dof.1999.024.06.545143] This is the same mechanism of action of pharmaceutical drugs such as galantamine and donepezil used to treat Alzheimer's disease. Huperzine A is also a NMDA receptor antagonistFact|date=September 2008 which protects the brain against glutamate induced damage, and it increases nerve growth factor levels.Fact|date=September 2008

Clinical trials in China have shown that huperzine A is comparably effective to the drugs currently on the market, and may even be a bit safer in terms of side effects.Fact|date=September 2008 Currently, the National Institute on Aging is conducting a Phase II clinical trial to evaluate the safety and efficiency of huperzine A in the treatment of Alzheimer's disease in a randomized controlled trial of its effect on cognitive function.Fact|date=September 2008 Recently, it has been investigated for its effectiveness against epilepsy in an initial 20-person clinical study by Harvard University neuroscientists examining its worth and side effects in those who are not satisfactorily treated by existing pharmaceuticals.Fact|date=September 2008

Side effects may include breathing problems, tightness in the throat or chest, chest pain, skin hives, rash, itchy or swollen skin, upset stomach, diarrhea, vomiting, hyperactivity and insomnia. [ [http://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/hup_0141.shtml PDR entry for Huperzine A] ]

ee also

* Acetylcholinesterase inhibitor

References